Trial Profile

A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary) ; Carboplatin; Cisplatin
Indications Carcinoma; Salivary gland cancer
Focus Therapeutic Use
Acronyms Post-op T-DM1

Most Recent Events

13 Apr 2026 Planned number of patients changed from 55 to 37.
24 Feb 2026 Planned End Date changed from 1 Feb 2027 to 1 Feb 2029.
24 Feb 2026 Planned primary completion date changed from 1 Feb 2026 to 1 Feb 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com